Trovagene Inc., of San Diego, reported summary data from a phase I study conducted by Nerviano Medical Sciences Inc., of Nerviano, Italy, with PCM-075, a polo-like kinase inhibitor, with thrombocytopenia and neutropenia identified as the primary dose-limiting toxicities, which the company described as consistent with the expected mechanism of action and results from preclinical studies.